Tissue distribution and excretion of intravenously administered titanium dioxide nanoparticles.


As the biosafety of nanotechnology becomes a growing concern, the in vivo nanotoxicity of nanoparticles (NPs) has been drawn an increasing attention. Titanium dioxide nanoparticles (TiO(2)-NPs) have been developed for versatile use, but the pharmacokinetics of intravenously administered TiO(2)-NPs have not been investigated extensively. In the present study… (More)
DOI: 10.1016/j.toxlet.2011.04.034


  • Presentations referencing similar topics